ID   Mel-XX4
AC   CVCL_A0GS
SY   MEL-XX4
DR   Wikidata; Q108820896
RX   Patent=US8501168;
RX   PubMed=17448240;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2829.
CC   HLA typing: A*24,33; B*18,65 (PubMed=17448240).
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   33Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 29-06-23; Version: 4
//
RX   Patent=US8501168;
RA   Mordoh J., Barrio M.M., von Euw E.M.;
RT   "Cell lines, compositions comprising them for the treatment of
RT   melanomas, procedures to prepare the compositions, and treatment
RT   methods.";
RL   Patent number US8501168, 06-Aug-2013.
//
RX   PubMed=17448240; DOI=10.1186/1479-5876-5-19;
RA   von Euw E.M., Barrio M.M., Furman D., Bianchini M., Levy E.M., Yee C.,
RA   Li Y.-Q., Wainstok de Calmanovici R., Mordoh J.;
RT   "Monocyte-derived dendritic cells loaded with a mixture of
RT   apoptotic/necrotic melanoma cells efficiently cross-present gp100 and
RT   MART-1 antigens to specific CD8(+) T lymphocytes.";
RL   J. Transl. Med. 5:19.1-19.13(2007).
//